0 min read
Science
Related posts

Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents
Critical reagents are essential components of ligand binding assays (LBAs) and are utilized throughout the process of drug discovery, development, and post-marketing monitoring.

Discovery of Therapeutic Antibodies to Difficult Membrane Proteins
Multi-pass trans-membrane and multimeric membrane proteins are targets for the development of therapeutic monoclonal antibodies.

Chemical Synthesis and X-ray Structure of a Heterochiral {D-protein antagonist plus vascular endothelial growth factor} Protein Complex by Racemic Crystallography
Total chemical synthesis was used to prepare the mirror image (D-protein) form of the angiogenic protein vascular endothelial growth factor (VEGF-A). Phage display against D-VEGF-A was used to screen designed libraries based on a unique small protein scaffold in order to identify a high affinity ligand.

Therapeutic Antibody Discovery at Antibody Solutions using the OmniAbTM Platform
Antibody Solutions performed its first program in OmniAbTM animals in September of 2012.

Discovery Platform for Therapeutic D-Proteins
Stereochemistry is a fundamental property of proteins that defines their shape and biologic function. Proteins made of L-amino acids have inherent limitations as drugs since they are degraded by proteases which reduce their halflife and are often neutralized by an immune reaction to the protein.

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both its Translation and Intracellular Stability
The human immunodeficiency virus type 1 (HIV-1) relies on Vif (viral infectivity factor) to overcome the potent antiviral function of APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, also known as CEM15).